The Latest Cardiac and Vascular News
– New labeling approval for Abbott’s XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR) – The new XIENCE Skypoint™ stent received FDA approval in the U.S. and CE Mark approval […]
June 30, 2021 Ultra-fast, less than one-minute scan time, cardiac MRI enables accurate assessment of heart anatomy and function, improves patient comfort, increases access to care, and reduces costs Technique can be implemented on existing MRI scanners Validated clinical trial results on more than 100 patients with diverse cardiac pathologies […]
Optimized for remote patient monitoring and decentralized clinical trials CAMPBELL, Calif., June 30, 2021 /PRNewswire/ — Vivalink, a leading provider of connected healthcare solutions known for its unique medical wearable sensor data platform, today announces a newly enhanced temperature and cardiac electrocardiogram (ECG) monitor. Adopted by over 100 healthcare application partners and customers […]
Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were presented at […]
Westport, CT, June 30, 2021 (GLOBE NEWSWIRE) — The Company recently increased its procedural volume targets due to accelerated technology usage BioSig expands its commercial team to target technology adoption across three strategic regions BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative […]
BOSTON, June 29, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the pricing of its upsized initial public offering of 8,682,142 shares of common stock at a […]
Constructive Feedback Helps Cardiology Practices Understand How to Improve their Remote Monitoring Programs BEND, Ore.–(BUSINESS WIRE)–Vector Remote Care announced today the launch of a Remote Cardiac Monitoring (RCM) Maturity Assessment to help cardiology practices understand both the current state of their program and how to grow and improve it to drive value […]
– KARDIA-1 will Evaluate Efficacy and Safety of Quarterly and Biannual Regimens of Zilebesiran as Monotherapy – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran (pronounced “zile-BEE-siran” and formerly known […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia. Javier San Martin, M.D., chief medical officer at […]
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces progress with finalizing the next-generation guidewire-compatible DABRA catheter design following a recent two-day, hands-on workshop with interventionalists who evaluated prototypes of the next-generation excimer […]
